LIP
IMRX icon

Lighthouse Investment Partners’s Immuneering IMRX Stock Holding History

Lighthouse Investment Partners’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,760
Closed -$117K – 879
2025
Q4 		$117K Buy
+17,760
New +$114K ﹤0.01% 790

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lighthouse Investment Partners's IMRX Position: Q1 2026 in Review

Lighthouse Investment Partners sold out of Immuneering (IMRX) in Q1 2026, closing a stake of 17,760 shares — an estimated $117K sold.

Lighthouse Investment Partners first reported a position in IMRX in Q4 2025 and held it in 1 quarter. The position peaked at $117K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Lighthouse Investment Partners reported no remaining Immuneering position as of Q1 2026 after selling out during the quarter.
  • Lighthouse Investment Partners sold 17,760 Immuneering shares in Q1 2026, an estimated $117K.
  • Lighthouse Investment Partners first reported a position in Immuneering in Q4 2025 and held it in 1 quarter.
  • Lighthouse Investment Partners's Immuneering position peaked at $117K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Lighthouse Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.